Find information on thousands of medical conditions and prescription drugs.

Lupus erythematosus

Lupus erythematosus (also known as systemic lupus erythematosus or SLE) is an autoimmune disorder in which antibodies are created against the patient's own DNA. It can cause various symptoms, but the main ones relate to the skin, kidney (lupus nephritis), joints, blood and immune system. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
Amyotrophic lateral...
Bardet-Biedl syndrome
Labyrinthitis
Lafora disease
Landau-Kleffner syndrome
Langer-Giedion syndrome
Laryngeal papillomatosis
Laryngomalacia
Lassa fever
LCHAD deficiency
Leber optic atrophy
Ledderhose disease
Legg-Calvé-Perthes syndrome
Legionellosis
Legionnaire's disease
Leiomyoma
Leiomyosarcoma
Leishmaniasis
Lemierre's syndrome
Lennox-Gastaut syndrome
Leprechaunism
Leprophobia
Leprosy
Leptospirosis
Lesch-Nyhan syndrome
Leukemia
Leukocyte adhesion...
Leukodystrophy
Leukomalacia
Leukoplakia
LGS
Li-Fraumeni syndrome
Lichen planus
Ligyrophobia
Limb-girdle muscular...
Limnophobia
Linonophobia
Lipodystrophy
Lipoid congenital adrenal...
Liposarcoma
Lissencephaly
Lissencephaly syndrome...
Listeriosis
Liticaphobia
Liver cirrhosis
Lobster hand
Locked-In syndrome
Loiasis
Long QT Syndrome
Long QT syndrome type 1
Long QT syndrome type 2
Long QT syndrome type 3
LSA
Lung cancer
Lupus erythematosus
Lyell's syndrome
Lygophobia
Lyme disease
Lymphangioleiomyomatosis
Lymphedema
Lymphoma
Lymphosarcoma
Lysinuric protein...
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

It is named for the Latin lupus, meaning "wolf", perhaps due to a crude similarity between the facial rash associated with the illness, and a wolf's face, although various explanations exist.

Signs and symptoms

Common initial and chronic complaints are fever, malaise, joint pains, myalgias and fatigue. Because they are so often seen with other diseases, these signs and symptoms are not part of the diagnostic criteria for SLE. When occurring in conjunction with other signs and symptoms, however, they are considered suggestive.

Dermatological manifestations

As many as 30% of patients present with some dermatological symptoms (and 65% suffer such symptoms at some point), with 30% to 50% suffering from the classic malar (or butterfly) rash associated with the disease. Patients may present with discoid lupus (thick, red scaly patches on the skin). Alopecia, mouth and vaginal ulcers, and lesions on the skin are also possible manifestations.

Musculoskeletal manifestations

Patients most often seek medical attention for joint pain, with small joints of the hand and wrist usually affected, although any joint is at risk. Unlike rheumatoid arthritis, SLE arthropathy is not usually destructive of bone, however, deformities caused by the disease may become irreversible in as many as 20% of patients.

Hematological manifestations

Anemia and iron deficiency may develop in as many as half of patients. Low platelet and white blood cell counts may be due to the disease or a side-effect of pharmacological treatment.

Cardiac manifestations

Patients may present with inflammation of various parts of the heart: pericarditis, myocarditis and endocarditis. The endocarditis of SLE is characteristically non-infective (Libman-Sacks endocarditis), and involves either the mitral valve or the tricuspid valve. Atherosclerosis also tends to occur more often and advance more rapidly in SLE patients than in the general population. (Asanuma et al 2003, Bevra 2003, Roman et al 2003).

Renal involvement

Painless hematuria or proteinuria may often be the only presenting renal symptom. Acute or chronic renal impairment may develop with lupus nephritis, leading to acute or end stage renal failure. Because of early recognition and management of SLE, end stage renal failure occurs in less than 5% of patients.

Neurological manifestations

About 10% of patients may present with seizures or psychosis. A third may test positive for abnormalities in the cerebrospinal fluid.

T-cell abnormalities

Abnormalities in T cell signaling are associated with SLE, including deficiency in CD45 phosphatase, increased expression of CD40 ligand. Also associated with SLE is increased expression of FcεRIγ, which replaces the TCR ζ chain, which is deficient in some SLE patients. Other abnormalities include:

Read more at Wikipedia.org


[List your site here Free!]


DHEA for systemic lupus erythematosus
From Townsend Letter for Doctors and Patients, 5/1/04 by Alan R. Gaby

One hundred-twenty women with active systemic lupus erythematosus (SLE) were randomly assigned to receive, in double-blind fashion, 200 mg/day of DHEA or placebo for 24 weeks. During the study, 18.3% of the patients in the DHEA group experienced a flare-up of their disease, compared with 33.9% of those in the placebo group. The incidence of disease flare-ups was 46% lower in the DHEA group than in the placebo group (p < 0.05). The mean change in the patients' global assessment was significantly better in the DHEA group than in the placebo group (14.9% improvement vs. 16.1% worsening; p = 0.005). The mean improvement in the Systemic Lupus Activity Measure score was 25.3% in the DHEA group and 19.3% in the placebo group (difference not significant). No serious side effects were seen, but DHEA treatment increased testosterone levels and increased the incidence of acne.

Comment: These results confirm those of earlier studies indicating that high-dose DHEA is beneficial in the treatment of women with SLE. Although DHEA caused acne in this study, it was otherwise well tolerated, and should be considered as part of the overall treatment of this potentially serious disease.

The markedly higher prevalence of SLE among women, as compared with men, suggests that high concentrations of androgens may somehow protect against the development of this disease. DHEA is a weak androgen that has been shown to reduce disease severity in animal models of lupus. Plasma levels of DHEA-sulfate have been found to be lower in patients with untreated SLE than in healthy controls. Furthermore, treatment with glucocorticoids such as prednisone will further deplete DHEA by shutting down its main source of production, the adrenal glands. Whether physiological doses of DHEA (such as 5-15 mg/day for women or 10-30 mg/day for men), as part of a comprehensive program of dietary modification and nutritional supplementation, would be beneficial has not been investigated, although some clinicians have the impression that it is helpful in some cases.

Chang DM, et al. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus. A multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:2924-2927.

COPYRIGHT 2004 The Townsend Letter Group
COPYRIGHT 2004 Gale Group

Return to Lupus erythematosus
Home Contact Resources Exchange Links ebay